Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Catheter Precision Inc VTAK

Catheter Precision, Inc. is a medical device company. It is engaged in providing new solutions to the market to improve the treatment of cardiac arrhythmias. It is focused on developing technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. It is also focused on developing and delivering electrophysiology products to provide patients, hospitals, and physicians with novel technologies and solutions to improve the lives of patients with cardiac arrhythmias. Its product is the VIVO System, which is an anacronym for View into Ventricular Onset System, which is a non-invasive imaging system that offers three-dimensional cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients. Its LockeT product is a suture retention device indicated for wound healing. Its product portfolio also includes the Amigo Remote Catheter System, a robotic arm that serves as a catheter control device.


NYSEAM:VTAK - Post by User

Post by averagepennieson Feb 22, 2024 8:59am
46 Views
Post# 35892848

Catheter Precision, Inc. Announces the Presentation

Catheter Precision, Inc. Announces the Presentation

FORT MILL, SC / ACCESSWIRE / February 22, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US-based medical device company focused on novel electrophysiology products, announced that the clinical data from the first LockeT study will be presented at the Western Atrial Fibrillation Symposium (Western AFib). The 17th annual Western AFib conference is taking place in Park City, Utah from February 23 - 24, 2024.

Catheter Precision's CEO, David Jenkins, said, "We are very excited to have the initial LockeT clinical data available to share with physicians. This study demonstrates that LockeT is not only safe and effective in achieving hemostasis but that it provides additional benefits of cost savings and same-day hospital discharge."

The Western Afib symposium is an internationally recognized meeting focused on improving outcomes worldwide and features experts from the atrial fibrillation community. Educational sessions are led by world-renowned faculty and include topics related to advancements in diagnosing and treating atrial fibrillation and focused roundtable discussions.

 

https://www.accesswire.com/835665/catheter-precision-inc-announces-the-presentation-of-the-first-clinical-data-on-locket

<< Previous
Bullboard Posts
Next >>